A phase II trial of AG10 in patients with ATTR polyneuropathy
Phase of Trial: Phase II
Latest Information Update: 11 May 2018
Price : $35 *
At a glance
- Drugs AG 10 (Primary)
- Indications Amyloid polyneuropathy
- Focus Therapeutic Use
- 11 May 2018 Status changed from not stated to planning.
- 11 May 2018 New trial record
- 03 May 2018 According to an Eidos Therapeutics media release, the company plans to initiate this trial later in 2018.